2012
Patterns of bone density evaluation in a community population treated with aromatase inhibitors
Ligibel JA, O’Malley A, Fisher M, Daniel GW, Winer EP, Keating NL. Patterns of bone density evaluation in a community population treated with aromatase inhibitors. Breast Cancer Research And Treatment 2012, 134: 1305-1313. PMID: 22791365, PMCID: PMC3449001, DOI: 10.1007/s10549-012-2151-0.Peer-Reviewed Original ResearchConceptsBone density testingBreast cancer patientsAromatase inhibitorsBone density evaluationAI therapyHealth maintenance organizationDensity testingCancer patientsHealthCore Integrated Research DatabaseMaintenance organizationYears of therapyCommunity-based populationLong-term therapyCommunity-based cohortMultivariable logistic regressionProton pump inhibitorsLow education levelRate of testingTamoxifen therapyTamoxifen useBone lossPharmacy dataPump inhibitorsBreast cancerBone density
2011
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809
Shapiro C, Halabi S, Hars V, Archer L, Weckstein D, Kirshner J, Sikov W, Winer E, Burstein H, Hudis C, Isaacs C, Schilsky R, Paskett E. Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: Final results from CALGB trial 79809. European Journal Of Cancer 2011, 47: 683-689. PMID: 21324674, PMCID: PMC4211594, DOI: 10.1016/j.ejca.2010.11.024.Peer-Reviewed Original ResearchConceptsChemotherapy-induced ovarian failureBone mineral densityRapid bone lossFollicle-stimulating hormoneZoledronic acidBone lossAdjuvant chemotherapyPremenopausal womenLumbar spineOvarian failureMineral densityMonths of amenorrhoeaGrade 3 toxicityMedian percent changeArm AAmino bisphosphonateMIU/Control groupPercent changeChemotherapyPercentage changeMonthsWomenRandomizationYears